Skip to main content

COVID-19

 

Clinical courses

 

Clinical research courses

  • Zymergen Advances Molecules for Prominent Malaria and COVID-19 Drug Targets for Further Testing

    Biotechnology company Zymergen is pleased to announce early results from its work on infectious disease, discovering hundreds of potential novel hits against malaria, tuberculosis, and COVID-19 targets. Hits for PfAPP, a critical target in the treatment of malaria, are now being advanced for validation, with hits for an emerging COVID-19 target, PLpro, expected to follow.

  • COVIFENZ Plant based COVID-19 Vaccine approved by Health Canada

    Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline announced that Health Canada has granted approval for COVIFENZ, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted). This vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID‑19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in individuals 18 to 64 years of age.

  • Repurposing FDA-approved drugs may help combat COVID-19

    Several FDA-approved drugs including for type 2 diabetes, hepatitis C and HIV significantly reduce the ability of the Delta variant of SARS-CoV-2 to replicate in human cells, according to new research led by scientists at Penn State. Specifically, the team found that these drugs inhibit certain viral enzymes, called proteases, that are essential for SARS-CoV-2 replication in infected human cells.

  • Indian made medicinal products illegally imported in Switzerland

    A large number of Indian made medicinal products illegally imported in Switzerland were seized by Swissmedic and the Federal Office for Customs and Border Security. These contained COVID-19 medicines like ivermectin, hydroxychloroquine or antibiotics and erectile stimulants from India.

    Swiss government agency along with customs had secured 9,421 packages containing illegally imported medicinal products during 2021. This is a significant increase on the previous year, when there were 6,733 such packages.

  • TRIPS waiver must be agreed for COVID-19, says MSF

    Medecins Sans Frontieres, International medical charity called on the European Union, the UK and Switzerland to swiftly adopt the landmark Waiver, which would lift intellectual property monopolies on COVID-19 medical tools, and is currently supported by more than 100 low and middle income countries. MSF also urged the US to show concrete leadership to accelerate the negotiations and to broaden the scope of its support beyond only vaccines to include medicines and diagnostics.

  • WHO grants prequalification of tocilizumab for patients with severe or critical COVID-19

    Roche announced that Actemra/RoActemra (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification. Prequalification is a confirmation by WHO that Actemra/RoActemra meets the WHO standards for quality, safety and efficacy for the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. It helps procurers in low- and middle-income countries identify priority medicines to improve access to care and support better health.

  • No needle required for newly developed inhaled COVID-19 vaccine delivery

    Scientists at McMaster University who have developed an inhaled form of COVID vaccine have confirmed it can provide broad, long-lasting protection against the original strain of SARS-CoV-2 and variants of concern.

    The research, recently published in the journal Cell, reveals the immune mechanisms and significant benefits of vaccines being delivered directly into the respiratory tract, rather than by traditional injection.

  • Glenmark launches COVID-19 nasal spray in India

    Glenmark Pharmaceuticals Limited a global, innovation-driven pharmaceutical company and Canadian pharmaceutical company SaNOtize Research & Development Corp. today announced launch of its Nitric Oxide Nasal Spray under the brand name FabiSpray in India; for the treatment of adult patients with COVID-19 who have high risk of progression of the disease. Glenmark earlier received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for NONS as part of the accelerated approval process.

  • Wockhardt gets CDSCO approval to export Sputnik Vaccines

    Wockhardt Limited has received permission from the Central Drugs Standard Control Organization (CDSCO) to export up to 80 million doses of Sputnik Light and up to 20 million doses of Sputnik V Component I vaccine.

    Wockhardts Bulk vaccine and Fill-Finish manufacturing facilities at Waluj and Shendra, Aurangabad respectively were jointly inspected and approved by Drug inspectors from CDSCO (West zone) & Aurangabad State FDA and Expert from CDL Kasauli to receive export NOC.

  • Study shows life-saving benefit of baricitinib for ventilated COVID patients

    Critically ill COVID-19 patients on a mechanical ventilator or extracorporeal membrane oxygenation lived more often when randomized to receive baricitinib. Doctors call this drug bari, and receiving the pill once a day for up to 14 days yielded one of the largest a survival advantages seen yet in the COVID pandemic, according to a study published.

Subscribe to COVID-19